Blood Cancer Talks

In this episode, we discuss the clinical implications of 10 high-impact abstracts presented at ASH 2022 with Dr. Manni Mohyuddin.

Show Notes

1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma
2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.
Link to the model:
3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma
4. Talquetamab: Phase 1/2 results from Monumental-1
5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosis
6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myeloma
7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
8. Three excellent abstracts from IstopMM:
Is MGUS associated with autoimmune disease?
Is isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?
Is MGUS associated with CKD?
9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trials
10. Surrogacy between PFS and OS in Multiple Myeloma

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk